30 results about "Menstrual bleeding" patented technology

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

A method of contraception that provides for sequentially administering to a female of child bearing age: (a) a first composition containing a progestin in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 22 to about 26 days; (b) a second composition containing an estrogen in an amount equivalent to about 5 to about 20 mcg of ethinyl estradiol for about 2 to about 3 days and an optional third composition that is a placebo provided that (i) if estrogen administration is continuous then the first composition is administered for 25 to 26 days, the second composition is administered for 2 to 3 days and no third composition is administered and (ii) if estrogen administration is not continuous then the first composition is administered for 22 to 24 days, the second composition is administered for 2 to 3 days and the third composition is administered for 1 to 4 days. The total cycle length is 28 days, with the first composition administered on day 1 of the menstrual cycle, defined as the first day of menstrual bleeding, or on the first Sunday after the first day of the menstrual cycle.

The present invention relates generally to benign gynecological diseases and in particular to a method and compositions for reducing heavy menstruation associated with said gynecological diseases following treatment with vascular occlusion methods or thermal related treatment methods.

The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment or prevention of disorders and diseases mediated by agonists and antagonists of the progesterone receptor. The clinical uses of these compounds are related to contraception, the treatment and / or prevention of secondary amenorrhea, dysfunctional bleeding, uterine leiomyomata, endometriosis; polycystic ovary syndrome, carcinomas and adenocarcinomas of the endometrium, ovary, breast, colon, prostate, or minication of side effects of cyclid menstrual bleeding. Additional uses of the invention include stimulation of food intake.

The invention provides a traditional Chinese medicine preparation for treating gynecological uterine bleeding, which is a pure Chinese medicine preparation for treating women's uterine bleeding caused by yin deficiency and yang beat, cold evil in the cells, and continuous dripping. The preparation is mainly composed of lotus leaf , lotus, fried cypress leaves, leaking reed, Chuanxiong, soaked dried ginger, cattail, codonopsis, osmanthus, roasted rehmannia, angelica, white peony, mulberry, horsetail, herbal cream, random hair, gardenia, akebia It is made of 31 Chinese herbal medicines, such as roasted cat placenta, etc. On this basis, it is supplemented with decoctions or pills made of 25 Chinese herbal medicines, such as Tian AI, Chinese yam, Cimicifuga, Scutellaria baicalensis, Zhishouwu, Anemarrhena, etc. , the formula of the present invention is rigorous and scientific, and its course of treatment is short, quick to take effect, gentle in property of medicine, safe. The cure rate for menstrual blood dripping metrorrhagia is 96%, and the effective rate is 99%. The cure rate for menstrual blood metrorrhagia is 95%, and the effective rate is 97%. The cure rate for both types of metrorrhagia is It was 93%, and the effective rate was 95%.

The invention discloses a blood activating and stasis removing Chinese medicinal formula for regulating little menstrual bleeding and a decoction method. The Chinese medicinal formula comprises the following components by weight: white hyacinth bean, licorice, fructus aurantii stir-fried with bran, glossy privet fruit, viscum coloratum, stir-fried salted eucommia ulmoides, polygonatum, radix astragali, codonopsis pilosula, Chinese angelica, prepared rhizome of rehmannia, Ligusticum wallichii, radix paeoniae alba, peach kernel, safflower, stir-fried cattail pollen, trogopterus dung and motherwort. According to the invention, compatibility of the white hyacinth bean, licorice, fructus aurantii stir-fried with bran, glossy privet fruit, viscum coloratum, stir-fried salted eucommia ulmoides, polygonatum, radix astragali and codonopsis pilosula has the efficacy of nourishing yin and benefiting kidney, tonifying Qi and soothing liver, promoting menstruation and harmonizing blood. The primaryefficacy of Chinese angelica is blood nourishing and menstruation regulating, and also has the efficacy of complexion lustering and skin moistening. Compatibility of prepared rhizome of rehmannia andChinese angelica can enhance the blood replenishing and blood activating efficacy of Chinese angelica. Ligusticum wallichii can affect the endocrine system, and alleviate breast discomfort, anxiety,depression and other premenstrual symptoms. Radix paeoniae alba can nourish blood and emolliate liver. Stir-fried cattail pollen can promote blood circulation and disperse stasis. trogopterus dung canbe used for treating stagnation of blood stasis and bleeding caused by escape of blood from vessels and channels. And motherwort can promote blood circulation, dispel stasis, regulate menstruation and eliminate water.

The present invention relates to a drug for treating dysfunctional uterine bleeding, the India madder root, Sanguis Draconis and carbonized human hair are mixed and smashed into the fine powder, the Chinese angelica, baical skullcap root, trogopterus dung, cattail pollen, south dodder seed etc. are boiled by water and then filtered and condensed into the thick paste, the drug powder is added for even mixing, finally the product is prepared by smashing and filling in the capsule. The drug of the present invention has the effects of nourishing blood, cooling blood, activating blood circulation,removing blood stasis and hemostasis, which is applicable to the treatment of the advanced menstruation of women, large amount of menstrual bleeding or large amount of uterine bleeding caused by contraceptive ring embedding and drug abortion and other diseases; the present invention has the advantages of easy administration, accurate efficacy and no toxicity or side effects etc. The total effectiverate can reach 96.0 percent through the clinical efficacy observations of 100 cases of patients with dysfunctional uterine bleeding.

The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one for the treatment and / or prophylaxis of Uterine Fibroids (myomas, uterine leiomyoma) that is administered to a patient diagnosed with Uterine Fibroids following a specific regimen. Additionally, the invention is directed to a method for treating Uterine Fibroids (myomas, uterine leiomyoma) and / or for reducing Uterine Fibroids (myomas, uterine leiomyoma) size and symptoms related to Uterine Fibroids following a specific regimen as well as treatment of Heavy Menstrual Bleeding (HMB).

The invention discloses an application of exosome from endometrium stem cells to medicines for treating acute lung injury. The endometrium stem cells are from menstrual bleeding of women. According tothe application disclosed by the invention, the endometrium stem cells are convenient to obtain and rich in source, an endometrium stem cell exosome preparation is simple to prepare, and an infusiontechnique is simple, convenient and easy to operate; and the exosome has significant effects on improving lung functions and reducing inflammation during acute lung injury, and has important clinicalsignificance and great application prospects.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof,in combination with estrogens and progestogens.

The invention relates to a traditional Chinese medicine for treating female hypomenorrhea caused by qi deficiency and blood deficiency, wherein the technical scheme is that the traditional Chinese medicine is prepared from the following bulk drugs by weight: 10-40 parts of Radix Rehmanniae Preparata, 15-40 parts of Radix Paeoniae Alba, 30-50 parts of Angelica sinensis, 20-50 parts of ginseng, 20-40 parts of Atractylodes macrocephala, 20-40 parts of tuckahoe, 10-40 parts of Cyperus rotundus L, and 20-60 parts of Leonurus artemisia. According to the present invention, the traditional Chinese medicine is suitable for the significantly reduced menstrual volume of less than 30 ml or the menstrual period of less than 2 days, little menstrual bleeding and other symptoms, can improve the qi deficiency and the blood deficiency of female bodies through blood enriching, nourishing, essence benefiting, marrow enriching, blood nourishing, ying-wei regulating, spleen strengthening and qi benefitingso as to relieve and cure hypomenorrhea, further has characteristics of significant treatment effect, no chemical component, no hormones, no side effect, easy taking, easy absorbing, quick effect andlow price, and is the pure traditional Chinese medicine preparation; and the clinical application observation results prove that the traditional Chinese medicine composition has characteristics of high efficiency and long acting.

The present invention relates to the method of treating heavy menstrual bleeding in a subject with or without uterine fibroids and in need of treatment by administering an effective amount of 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1-phenyl-ethylamino)-butyric acid or a pharmaceutically acceptable salt thereof, in combination with estrogens and progestogens.

The invention is directed to a pharmaceutical composition comprising a progesterone receptor antagonist namely (11beta,17beta)-17-Hydroxy-11-[4-(methylsulphonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one at the dosage of about 0.5 to 5 mg and more particularly 2 mg. Additionally, the invention is directed to the use of the novel pharmaceutical composition for treatment of and / or prophylaxisof gynaecological diseases, such as fibroids of the uterus (myomas, uterine leiomyoma), endometriosis or excessive menstrual bleeds, and method for obtaining such composition and oral dosage form.